Musculoskeletal Effects of Antineoplastic Agents.

J Am Acad Orthop Surg · Nov 15 2019 · Review

Sutton K, Sanft TB, Knobf TM, Ibe IK

From the Department of Oncology, Yale New Haven Hospital, Yale University (Dr. Sutton and Dr. Knobf), CT (Dr. Sanft)

Orthopaedic Oncology

SUMMARY — THE REDUCTIONReviews musculoskeletal adverse effects of common chemotherapy and targeted agents such as taxanes, helping orthopaedic surgeons recognize treatment-related complaints in the growing population of cancer survivors.
Abstract, as published

Cancer remains a common disease with approximately 40% of Americans diagnosed with cancer in their lifetime. Medical advances in the field of oncology have led to an increased life expectancy and a decreased mortality rate. Antineoplastic agents such as taxanes and targeted therapies are indicated in the treatment of many cancers, and their use can be associated with various musculoskeletal complaints and adverse effects. Orthopaedic Surgeons are trained to identify primary bone tumors and metastasis to bones. It is also important for them to have an understanding of the profile of musculoskeletal adverse effects associated with the treatment of the more common neoplasms. This article reviews the current literature on the commonly used chemotherapeutic agents and their associated musculoskeletal effects.

Featured in the 2026-10-23 issue.

← Advances in limb salvage treatment of osteosarcomaSocioeconomic disparities in musculoskeletal oncology. →

The Reduction is a free email digest of newly published orthopaedic literature — a handful of new papers in the subspecialties you choose, each summarized like this one. Subscribe free or browse the archive.